Abstract: A composition to improve hyperpigmentation is disclosed. The composition has one or more active ingredients such as tranexamic acid, niacinamide, arbutin, and Vitamin C. The composition has water, caprylic/capric triglyceride, C12-15 Alkyl Benzoate, Isononyl Isononanoate, Silica, Glyceryl Stearate and PEG-100 Stearate, Cetearyl Alcohol and Ceteareth-20, Xylitylglucoside and Anhydroxylitol and Xylitol, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Polysorbate 60, Phenoxyethanol and Ethylhexylglycerin, Citric Acid, Titanium Dioxide, Citrus oil, sh-Polypeptide-22, and sh-Oligopeptide-1. The composition is a non-HQ formulation that provides equal or greater efficacy with a reduced adverse reaction profile to improve skin hyperpigmentation, such as melasma, post-inflammatory hyperpigmentation, and solar lentigines. The composition reduces skin damage and provides toning to the skin.

Abstract: A composition to improve hyperpigmentation is disclosed. The composition has one or more active ingredients such as tranexamic acid, niacinamide, arbutin, and Vitamin C. The composition has water, caprylic/capric triglyceride, C12-15 Alkyl Benzoate, Isononyl Isononanoate, Silica, Glyceryl Stearate and PEG-100 Stearate, Cetearyl Alcohol and Ceteareth-20, Xylitylglucoside and Anhydroxylitol and Xylitol, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Polysorbate 60, Phenoxyethanol and Ethylhexylglycerin, Citric Acid, Titanium Dioxide, Citrus oil, sh-Polypeptide-22, and sh-Oligopeptide-1. The composition is a non-HQ formulation that provides equal or greater efficacy with a reduced adverse reaction profile to improve skin hyperpigmentation, such as melasma, post-inflammatory hyperpigmentation, and solar lentigines. The composition reduces skin damage and provides toning to the skin.

Abstract: A device for measuring facial anatomical parameters is provided. The device has a vertical bar having a top portion, middle portion, and a bottom portion and a horizontal slide adjustably affixed to the vertical bar. It has a forehead positioner pivotably and adjustably affixed to the top portion of the vertical bar, wherein the forehead positioner receives a forehead of the patient, a first mirror adjustably affixed to the left portion of the horizontal slide, wherein the first mirror is slidable along the horizontal slide, and wherein the first mirror rotates around its own Y-axis, and a second mirror adjustably affixed to the right portion of the horizontal slide, wherein the second mirror is slidable along the horizontal slide. A measuring grid on or proximate both the first mirror and the second mirror, wherein the measuring grids allows an examiner to accurately measure a point of interest of the facial anatomic parameters.

Abstract: A device for treating eyes, eyelids or both, in the form of a handheld housing is disclosed herein. The device has a first chamber, a second chamber acting as a vapor reservoir, and hydrophilic material disposed within the first chamber. The hydrophilic material has a plurality of pores configured to allow the fluid to seep from the first chamber to the hydrophilic material. A heating element is positioned adjacent the hydrophilic material to convert the fluid to a vapor and continuously regulate a temperature of the vapor. A user interface is disposed on an outside of the housing and configured to control a variable circulator, which in turn controls the temperature of the vapor reaching the user. A method for treating eyes, eyelids, or both is also disclosed.

Abstract: A device for treating eyes, eyelids or both, in the form of a handheld housing is disclosed herein. The device has a first chamber a second chamber acting as a vapor reservoir, and hydrophilic material disposed within the first chamber. The hydrophilic material having has a plurality of pores configured to allow the fluid to seep from the first chamber to the hydrophilic material. A heating element is positioned adjacent the hydrophilic material to convert the fluid to a vapor and continuously regulate a temperature of the vapor. A user interface is disposed on an outside of the housing and configured to control a variable circulator which in turn controls control the temperature of the vapor reaching the user. A method for treating eyes, eyelids, or both is also disclosed.

Abstract: A device for measuring facial anatomical parameters is provided. The device has a vertical bar having a top portion, middle portion, and a bottom portion and a horizontal slide adjustably affixed to the vertical bar. It has a forehead positioner pivotably and adjustably affixed to the top portion of the vertical bar, wherein the forehead positioner receives a forehead of the patient, a first mirror adjustably affixed to the left portion of the horizontal slide, wherein the first mirror is slidable along the horizontal slide, and wherein the first mirror rotates around its own Y-axis, and a second mirror adjustably affixed to the right portion of the horizontal slide, wherein the second mirror is slidable along the horizontal slide. A measuring grid on or proximate both the first mirror and the second mirror, wherein the measuring grids allows an examiner to accurately measure a point of interest of the facial anatomic parameters.

Abstract: A composition for treating cutaneous condition is provided and has 0.001-1.000 wt. % Aloe barbadensis Leaf Juice, 1.000-40.000 wt. % Cyclopentasiloxane and Dimethicone Crosspolymer, 0.50-15.000 wt. % Dimethicone, 1.00-10.000 wt. % Ethoxydiglycol, 0.100-5.000 wt. % Glycerin, Water and Centella asiatica Extract Mixture, 1.000-30.000 wt. % Glycerin, 0.500-5.000 wt. % Hydroxyethyl Acetate/Sodium Acryloyldimethy Taurate Copolymer, 0.600-1.100 wt. % Phenoxyyethanoland Ethylexylglycerin, 1-6.00 wt. fry PPG-12 SMDI Copolymer, 0.00100-0.1000 wt. % GMP Grade Recombinant Human TGF-B3, 0.010-0.3000 wt. % GMP Grade Recombinant Human IL10, 0.010-0.9000 wt. % GMP Grade Recombinant Human bFGF, 0.010-2.00 wt, % Sodium Hyaluronate, 0.1000-10.000 wt. % Tetrahexyldecyl Ascorbate, 30.000-80.000 wt % Water.

Abstract: A composition for treating cutaneous condition is provided and has 0.200 wt. % Aloe Barbadensis Leaf Juice, 10.000 wt. % Cyclopentasiloxane and Dimethicone Crosspolymer, 6.000 wt. % Dimethicone, 2.000 wt. % Ethoxydiglycol, 2.000 wt. % Glycerin, Water and Centella Asiatica Extract Mixture, 18.000 wt. % Glycerin, 3.000 wt. % Hydroxyethyl Acetate/Sodium Acryloyldimethy Taurate Copolymer, 1.100 wt. % Phenoxyyethanol and Ethylexylglycerin, 2.00 wt. % PPG-12 SMDI Copolymer, 0.004 wt. % GMP Grade Recombinant Human TGF-B3, 0.075 wt. % GMP Grade Recombinant Human IL10, 0.250 wt. % GMP Grade Recombinant Human bFGF, 0.500 wt. % Sodium Hyaluronate, 2.000 wt. % Tetrahexyldecyl Ascorbate, and water to make 100%.

Abstract: A device for treating eyes, eyelids or both, in the form of a handheld housing is disclosed herein. The device has a first chamber configured as a fluid reservoir, a second chamber opened on a top end of a housing and configured as a steam reservoir, a hydrophilic material disposed within the first chamber, the hydrophilic material having a plurality of pours configured to allow the fluid to seep from the first chamber to the hydrophilic material, a heating element positioned adjacent hydrophilic material and the second chamber, the heating element configured to convert the liquid to a vapor and continuously regulate a temperature of the steam and a user interface disposed on an outside of the housing and configured to control a variable circulator, the variable circulator being positioned in an orifice at the top end of the housing, the variable circulator functioning to control the temperature of the vapor reaching the user. A method for treating eyes, eyelids, or both is also disclosed.

Abstract: A composition for treating cutaneous condition is provided and has 0.001-1.000 wt. % Aloe Barbadensis Leaf Juice, 1.000-40.000 wt. % Cyclopentasiloxane and Dimethicone Crosspolymer, 0.50-15.000 wt. % Dimethicone, 1.00-10.000 wt. % Ethoxydiglycol, 0.100-5.000 wt. % Glycerin, Water and Centella Asiatica Extract Mixture, 1.000-30.000 wt. % Glycerin, 0.500-5.000 wt. % Hydroxyethyl Acetate/Sodium Acryloyldimethy Taurate Copolymer, 0.600-1.100 wt. % Phenoxyyethanoland Ethylexylglycerin, 1-6.00 wt. % PPG-12 SMDI Copolyper, 0.00100-0.1000 wt. % GMP Grade Recombinant Human TGF-B3, 0.010-0.3000 wt. % GMP Grade Recombinant Human IL10, 0.010-0.9000 wt. % GMP Grade Recombinant Human bFGF, 0.010-2.00 wt. % Sodium Hyaluronate, 0.1000-10.000 wt. % Tetrahexyldecyl Ascorbate, 30.000-80.000 wt % Water.